vTv Therapeutics (NASDAQ:VTVT - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect vTv Therapeutics to post earnings of ($0.87) per share for the quarter.
vTv Therapeutics Trading Down 6.4 %
VTVT traded down $1.07 during trading on Friday, hitting $15.61. 10,793 shares of the company's stock were exchanged, compared to its average volume of 20,881. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $30.99. The stock has a 50 day moving average price of $16.35 and a 200 day moving average price of $15.39. The firm has a market cap of $49.80 million, a P/E ratio of -3.45 and a beta of 1.07.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of vTv Therapeutics in a research note on Monday, March 3rd. They set a "sell" rating for the company. Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They set a "buy" rating and a $35.00 price objective for the company.
Get Our Latest Report on VTVT
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Further Reading
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
